Literature DB >> 28093255

NLRP3 gene knockout blocks NF-κB and MAPK signaling pathway in CUMS-induced depression mouse model.

Wen-Jun Su1, Yi Zhang2, Ying Chen3, Hong Gong1, Yong-Jie Lian1, Wei Peng1, Yun-Zi Liu1, Yun-Xia Wang1, Zi-Li You4, Shi-Jie Feng5, Ying Zong5, Guo-Cai Lu6, Chun-Lei Jiang7.   

Abstract

BACKGROUND: Abundant researches indicate that neuroinflammation has important roles in the pathophysiology of depression. Our previous study found that the NLRP3 inflammasome mediated stress-induced depression-like behavior in mice via regulating neuroinflammation. However, it still remains unclear that how the NLRP3 inflammasome influences related inflammatory signaling pathway to contribute to neuroinflammation in depression.
METHODS: We used wild-type mice and NLRP3 gene knockout mice to explore the role of NLRP3 inflammasome and related inflammatory signaling pathways in chronic unpredictable mild stress (CUMS) induced depression mouse model.
RESULTS: Both wild-type and NLRP3 knockout stress group mice gained less weight than control group mice after 4 weeks CUMS exposure. The wild-type mice subjected to 4 weeks CUMS displayed depression-like behaviors, including decreased sucrose preference and increased immobility time in the tail suspension test. The NLRP3 knockout stress group mice didn't demonstrate depression-like behaviors. The levels of interleukin-1β protein in serum and hippocampi of CUMS exposed wild-type mice were significantly higher, while the NLRP3 knockout stress group mice didn't show an elevation of interleukin-1β levels. Similarly to early researches, we found that CUMS led to promoted NLRP3 expression in hippocampi. In addition, the hippocampi in CUMS exposed wild-type mice had higher p-JNK and p-p38 protein expression, which indicated activation of the mitogen-activated protein kinases (MAPK) pathway. The knockout of NLRP3 gene inhibited CUMS-induced activation of the MAPK pathway. The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) protein complex was activated in the hippocampi of wild-type mice after CUMS exposure, while knockout of NLRP3 gene hindered its activation.
CONCLUSIONS: These data further proved that the NLRP3 inflammasome mediated CUMS-induced depression-like behavior. The NLRP3 inflammasome regulated CUMS-induced MAPK pathway and NF-κB protein complex activation in depression mouse model. Further researches targeting the NLRP3 inflammasome-signaling pathway might be under a promising future in the prevention and treatment of depression.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Inflammation; Interleukin-1β; Knockout; NLRP3 inflammasome; Stress

Mesh:

Substances:

Year:  2017        PMID: 28093255     DOI: 10.1016/j.bbr.2017.01.018

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  50 in total

1.  Neferine inhibits LPS-ATP-induced endothelial cell pyroptosis via regulation of ROS/NLRP3/Caspase-1 signaling pathway.

Authors:  Yang-Shuo Tang; Yan-Hua Zhao; Yong Zhong; Xiao-Zhao Li; Jia-Xi Pu; Yan-Cheng Luo; Qiao-Ling Zhou
Journal:  Inflamm Res       Date:  2019-06-06       Impact factor: 4.575

2.  Inflammatory cytokines derived from peripheral blood contribute to the modified electroconvulsive therapy-induced cognitive deficits in major depressive disorder.

Authors:  Haihua Tian; Guangxue Li; Guoan Xu; Jimeng Liu; Xiaohan Wan; Jiao Zhang; Shuguang Xie; Jia Cheng; Shugui Gao
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-02       Impact factor: 5.270

3.  Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-κB pathways.

Authors:  Mengqi Yang; Ruili Dang; Pengfei Xu; Yujin Guo; Wenxiu Han; Dehua Liao; Pei Jiang
Journal:  Psychopharmacology (Berl)       Date:  2018-06-25       Impact factor: 4.530

4.  Potential role of BAY11-7082, a NF-κB blocker inhibiting experimental autoimmune encephalomyelitis in C57BL/6J mice via declining NLRP3 inflammasomes.

Authors:  Yue Lang; Fengna Chu; Lingling Liu; Chao Zheng; Chunrong Li; Donghui Shen; Shan Liu; Weiguanliu Zhang; Li Cui; Jie Zhu
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

5.  Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways.

Authors:  Xiang Xu; Hu-Nan Piao; Fumie Aosai; Xiao-Yu Zeng; Jia-Hui Cheng; Yue-Xian Cui; Jing Li; Juan Ma; Hu-Ri Piao; Xuejun Jin; Lian-Xun Piao
Journal:  Br J Pharmacol       Date:  2020-10-19       Impact factor: 8.739

6.  Persistent Increase in Microglial RAGE Contributes to Chronic Stress-Induced Priming of Depressive-like Behavior.

Authors:  Tina C Franklin; Eric S Wohleb; Yi Zhang; Manoela Fogaça; Brendan Hare; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2017-07-21       Impact factor: 13.382

Review 7.  Current Status of Animal Models of Posttraumatic Stress Disorder: Behavioral and Biological Phenotypes, and Future Challenges in Improving Translation.

Authors:  Jessica Deslauriers; Mate Toth; Andre Der-Avakian; Victoria B Risbrough
Journal:  Biol Psychiatry       Date:  2017-11-20       Impact factor: 13.382

8.  Trans-10-hydroxy-2-decenoic acid protects against LPS-induced neuroinflammation through FOXO1-mediated activation of autophagy.

Authors:  Mengmeng You; Zhuoning Miao; Jing Tian; Fuliang Hu
Journal:  Eur J Nutr       Date:  2019-12-09       Impact factor: 5.614

9.  The protective effect of Lonicera japonica polysaccharide on mice with depression by inhibiting NLRP3 inflammasome.

Authors:  Ping Liu; Xinyu Bai; Tao Zhang; Limei Zhou; Jing Li; Lan Zhang
Journal:  Ann Transl Med       Date:  2019-12

10.  Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway.

Authors:  Anderson Camargo; Ana Paula Dalmagro; Daiane B Fraga; Julia M Rosa; Ana Lúcia B Zeni; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  Psychopharmacology (Berl)       Date:  2021-08-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.